What studies of magnesium found
At a glance, by condition
Long COVID: C Might help, very uncertain
Based on the strongest evidence, the randomised trial and compared with another group, not randomised (very low certainty): 1 of 2 findings is C, a tie, so the grade of depression, as the rule below says.
2 outcomes rated · see each below
ME/CFS: B May help
Based on the strongest evidence, the placebo trial (low certainty), for overall symptoms.
5 outcomes rated · see each below
How we got this
Each condition’s headline comes from its graded findings (one for each outcome and kind of study) rated with the highest certainty: the grade most of them share; a tie goes to the finding with the most people, then the most studies, then the outcome’s name. It sums up the grades below, and conditions are never combined.
What this means: For long COVID, magnesium might help some people, but research can’t show it yet. For ME/CFS, magnesium may help, but the evidence is still limited. If you’re thinking about it, talk it through with a doctor who knows ME/CFS or long COVID.
Ask about this treatment
The grades, in plain words
Each outcome gets a direction, a certainty and a letter read from the two. Certainty is judged with GRADE, the method Cochrane and WHO use.
- AHelpsImprovement, high certaintyProbably helpsImprovement, moderate certainty
- Magnesium · ME/CFS is hereBMay helpImprovement, low certainty
- Magnesium · Long COVID is hereCMight help, very uncertainImprovement, very low certaintyMixed resultsStudies disagree
- DLittle or no differenceStudies found little or no difference
- FHarmsIt made things worse
By symptom and daily life
Long COVID
Symptoms
Depression1 study · 30 people took magnesium Improvement C
Why this grade: Improvement, very low certainty, from randomised trials: high risk of bias (RoB 2) in the results that carry most of the weight; few people (60 in all).
The randomised trial60 randomised · for four months · 1300 mg
Depression improved more than in the comparison group.
The evidence is very uncertain about the effect of magnesium on depression in long COVID. Improvement · very low certainty C
- High risk of bias (RoB 2) in the results that carry most of the weight
- Few people (60 in all)
See the 1 study
-
- People in the study
- 60 randomised
- Dose
- 1300 mg
- Outcome
- improvement in depressive symptoms (BDI <11) Beck Depression Inventory
- Effect
- better
- Risk of bias
RoB 2: High
- Randomisation process
- Some concerns
- Deviations from intended interventions
- High
- Missing outcome data
- High
- Measurement of the outcome
- High
- Selection of the reported result
- Some concerns
Daily life and health overall
Overall symptoms1 study · 4 (few people) people took magnesium Little or no difference D
Why this grade: Little or no difference, very low certainty, from controlled studies: serious risk of bias (ROBINS-I); few people (8 in all).
Compared with another group, not randomised8 in the study · six weeks · 400mg/d, one capsule per day throughout the intervention period, preferably after lunch (few people)
No clear difference in overall symptoms.
The evidence is very uncertain about the effect of magnesium on overall symptoms in long COVID. Little or no difference · very low certainty D
- Serious risk of bias (ROBINS-I)
- Few people (8 in all)
Combination: Magnesium + Selenium + CoQ10 / ubiquinol3 in the study
Translating Results from The Womed Model of Benign Thyroid Disease to A Practical Approach to Treat Fatigue In COVID-19 Patients Based on Combined Supplementation with Magnesium, Selenium, and Coenzyme Q10: A Treatment Strategy against Fatigue (2020): clinical condition, better (not tested).
Shown, not counted: magnesium was given together with other treatments.
See the 1 study
-
- People in the study
- 8 in the study
- Dose
- 400mg/d, one capsule per day throughout the intervention period, preferably after lunch
- Outcome
- DSQ-Covid score DePaul Symptom Questionnaire – COVID (DSQ-COVID)
- Effect
- no clear difference
- Risk of bias
ROBINS-I: Serious
- Confounding
- NI. adjustment for confounding isn't reported
- Selection of participants
- Moderate. comparison group: first randomized by sortition, then order of entrance
Allocation of the first participant was randomized by sortition. Then, allocation followed the order of entrance into the study.
- Classification of interventions
- Low. assigned and recorded at the start
- Deviations from intended interventions
- NI. not reported for this design
- Missing data
- Serious. only people who finished were analysed
Eight participants signed the Informed Consent Form and finished the procedures.
- Measurement of outcomes
- Serious. self-reported by people who knew their treatment
- Selection of the reported result
- NI. whether this outcome was pre-specified isn't reported
ME/CFS
Symptoms
Fatigue2 studies · 16 people took magnesium Improvement C
Why this grade: Improvement, very low certainty, from randomised trials: high risk of bias (RoB 2) in the results that carry most of the weight; few people (32 in all).
The placebo trial38 randomised · 32 started · a week after the last injection, after a 6-week course: "Before the first injection and a week after the last, patients were asked to complete the Nottingham health profile" · 1 g in 2 ml, every week for 6 weeks
Fatigue improved more than in the comparison group.
The evidence is very uncertain about the effect of magnesium on fatigue in ME/CFS. Improvement · very low certainty C
- High risk of bias (RoB 2) in the results that carry most of the weight
- Few people (32 in all)
Studies with no comparison group1 in the study · about 6-week's administration · once a week (few people)
Fatigue improved.
The evidence is very uncertain about the effect of magnesium on fatigue in ME/CFS. Improvement · very low certainty C
- No control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design)
- Few people (1 in all)
- Not all results were tested against chance
Combination: CoQ10 / ubiquinol + Alpha-lipoic acid (ALA, R-ALA) + NAC (N-acetylcysteine) + L-carnitine + Magnesium + Vitamin C + Vitamin D and sun exposure + Vitamin E (tocopherol, tocotrienols) + Vitamin A (retinol) + Biotin + Thiamine / benfotiamine + Riboflavin (vitamin B2) + Niacinamide (nicotinamide) + Pantothenic acid (vitamin B5) + Vitamin B6 (pyridoxine, P5P) + Folate / folic acid supplements + Vitamin B1210 in the study
Mitochondrial modifying nutrients in treating chronic fatigue syndrome: A 16-week open-label pilot study (2017): Chalder Fatigue Scale (CFQ), better.
Shown, not counted: magnesium was given together with other treatments.
See the 2 studies
-
Red blood cell magnesium and chronic fatigue syndrome. (1991)
- People in the study
- 38 randomised · 32 started
- Dose
- 1 g in 2 ml, every week for 6 weeks
- Outcome
- energy Nottingham health profile
- Effect
- better
- Risk of bias
RoB 2: High
- Randomisation process
- Some concerns
- Deviations from intended interventions
- High
- Missing outcome data
- High
- Measurement of the outcome
- Low
- Selection of the reported result
- Some concerns
-
- People in the study
- 1 in the study
- Dose
- once a week
- Outcome
- reduced easy fatigability
- Effect
- better (not tested)
- Risk of bias
- case report or series (JBI checklist for case reports / case series); not rated with RoB 2 or ROBINS-I
Low mood or anxiety1 study · 15 people took magnesium Improvement C
Why this grade: Improvement, very low certainty, from randomised trials: high risk of bias (RoB 2) in the results that carry most of the weight; few people (32 in all).
The placebo trial38 randomised · 32 started · a week after the last injection, after a 6-week course: "Before the first injection and a week after the last, patients were asked to complete the Nottingham health profile" · 1 g in 2 ml, every week for 6 weeks
Low mood or anxiety improved more than in the comparison group.
The evidence is very uncertain about the effect of magnesium on low mood or anxiety in ME/CFS. Improvement · very low certainty C
- High risk of bias (RoB 2) in the results that carry most of the weight
- Few people (32 in all)
See the 1 study
-
Red blood cell magnesium and chronic fatigue syndrome. (1991)
- People in the study
- 38 randomised · 32 started
- Dose
- 1 g in 2 ml, every week for 6 weeks
- Outcome
- emotional reactions Nottingham health profile
- Effect
- better
- Risk of bias
RoB 2: High
- Randomisation process
- Some concerns
- Deviations from intended interventions
- High
- Missing outcome data
- High
- Measurement of the outcome
- Low
- Selection of the reported result
- Some concerns
Pain1 study · 15 people took magnesium Improvement C
Why this grade: Improvement, very low certainty, from randomised trials: high risk of bias (RoB 2) in the results that carry most of the weight; few people (32 in all).
The placebo trial38 randomised · 32 started · a week after the last injection, after a 6-week course: "Before the first injection and a week after the last, patients were asked to complete the Nottingham health profile" · 1 g in 2 ml, every week for 6 weeks
Pain improved more than in the comparison group.
The evidence is very uncertain about the effect of magnesium on pain in ME/CFS. Improvement · very low certainty C
- High risk of bias (RoB 2) in the results that carry most of the weight
- Few people (32 in all)
See the 1 study
-
Red blood cell magnesium and chronic fatigue syndrome. (1991)
- People in the study
- 38 randomised · 32 started
- Dose
- 1 g in 2 ml, every week for 6 weeks
- Outcome
- pain Nottingham health profile
- Effect
- better
- Risk of bias
RoB 2: High
- Randomisation process
- Some concerns
- Deviations from intended interventions
- High
- Missing outcome data
- High
- Measurement of the outcome
- Low
- Selection of the reported result
- Some concerns
Daily life and health overall
Overall symptoms2 studies · 16 people took magnesium Improvement B
Why this grade: Improvement, low certainty, from randomised trials: some concerns about bias (RoB 2); few people (32 in all).
The placebo trial38 randomised · 32 started · a week after the last injection, after a 6-week course: "Before the first injection and a week after the last, patients were asked to complete the Nottingham health profile" · 1 g in 2 ml, every week for 6 weeks
Overall symptoms improved more than in the comparison group.
Magnesium may improve overall symptoms in ME/CFS. Improvement · low certainty B
- Some concerns about bias (RoB 2)
- Few people (32 in all)
Studies with no comparison group1 in the study · about 6-week's administration · once a week (few people)
Overall symptoms improved.
The evidence is very uncertain about the effect of magnesium on overall symptoms in ME/CFS. Improvement · very low certainty C
- No control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design)
- Few people (1 in all)
- Not all results were tested against chance
Combination: CoQ10 / ubiquinol + Alpha-lipoic acid (ALA, R-ALA) + NAC (N-acetylcysteine) + L-carnitine + Magnesium + Vitamin C + Vitamin D and sun exposure + Vitamin E (tocopherol, tocotrienols) + Vitamin A (retinol) + Biotin + Thiamine / benfotiamine + Riboflavin (vitamin B2) + Niacinamide (nicotinamide) + Pantothenic acid (vitamin B5) + Vitamin B6 (pyridoxine, P5P) + Folate / folic acid supplements + Vitamin B1210 in the study
Mitochondrial modifying nutrients in treating chronic fatigue syndrome: A 16-week open-label pilot study (2017): CGI-I, better.
Shown, not counted: magnesium was given together with other treatments.
See the 2 studies
-
Red blood cell magnesium and chronic fatigue syndrome. (1991)
- People in the study
- 38 randomised · 32 started
- Dose
- 1 g in 2 ml, every week for 6 weeks
- Outcome
- benefited from treatment
- Effect
- better
- Risk of bias
RoB 2: Some concerns
- Randomisation process
- Some concerns
- Deviations from intended interventions
- Some concerns
- Missing outcome data
- Low
- Measurement of the outcome
- Low
- Selection of the reported result
- Some concerns
-
- People in the study
- 1 in the study
- Dose
- once a week
- Outcome
- able to leave the hospital
- Effect
- better (not tested)
- Risk of bias
- case report or series (JBI checklist for case reports / case series); not rated with RoB 2 or ROBINS-I
Daily functioning1 study · 1 (few people) person took magnesium Improvement C
Why this grade: Improvement, very low certainty, from studies without a control group: no control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design); few people (1 in all); not all results were tested against chance.
Studies with no comparison group1 in the study · about 6-week's administration · once a week (few people)
Daily functioning improved.
The evidence is very uncertain about the effect of magnesium on daily functioning in ME/CFS. Improvement · very low certainty C
- No control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design)
- Few people (1 in all)
- Not all results were tested against chance
Combination: CoQ10 / ubiquinol + Alpha-lipoic acid (ALA, R-ALA) + NAC (N-acetylcysteine) + L-carnitine + Magnesium + Vitamin C + Vitamin D and sun exposure + Vitamin E (tocopherol, tocotrienols) + Vitamin A (retinol) + Biotin + Thiamine / benfotiamine + Riboflavin (vitamin B2) + Niacinamide (nicotinamide) + Pantothenic acid (vitamin B5) + Vitamin B6 (pyridoxine, P5P) + Folate / folic acid supplements + Vitamin B1210 in the study
Mitochondrial modifying nutrients in treating chronic fatigue syndrome: A 16-week open-label pilot study (2017): WSAS, no clear difference.
Shown, not counted: magnesium was given together with other treatments.
See the 1 study
-
- People in the study
- 1 in the study
- Dose
- once a week
- Outcome
- improvement in her impaired daily activities
- Effect
- better (not tested)
- Risk of bias
- case report or series (JBI checklist for case reports / case series); not rated with RoB 2 or ROBINS-I
Studies of combinations
Outcomes that only studies of magnesium given together with other treatments looked at. Shown, not graded: they can’t tell what magnesium did alone.
Cognition (brain fog) ME/CFS
Combination: CoQ10 / ubiquinol + Alpha-lipoic acid (ALA, R-ALA) + NAC (N-acetylcysteine) + L-carnitine + Magnesium + Vitamin C + Vitamin D and sun exposure + Vitamin E (tocopherol, tocotrienols) + Vitamin A (retinol) + Biotin + Thiamine / benfotiamine + Riboflavin (vitamin B2) + Niacinamide (nicotinamide) + Pantothenic acid (vitamin B5) + Vitamin B6 (pyridoxine, P5P) + Folate / folic acid supplements + Vitamin B1210 in the study
Mitochondrial modifying nutrients in treating chronic fatigue syndrome: A 16-week open-label pilot study (2017): memory, item 11, and problems starting things, item 4, no clear difference.
Shown, not counted: magnesium was given together with other treatments.
Depression ME/CFS
Combination: CoQ10 / ubiquinol + Alpha-lipoic acid (ALA, R-ALA) + NAC (N-acetylcysteine) + L-carnitine + Magnesium + Vitamin C + Vitamin D and sun exposure + Vitamin E (tocopherol, tocotrienols) + Vitamin A (retinol) + Biotin + Thiamine / benfotiamine + Riboflavin (vitamin B2) + Niacinamide (nicotinamide) + Pantothenic acid (vitamin B5) + Vitamin B6 (pyridoxine, P5P) + Folate / folic acid supplements + Vitamin B1210 in the study
Mitochondrial modifying nutrients in treating chronic fatigue syndrome: A 16-week open-label pilot study (2017): total MADRS score, no clear difference.
Shown, not counted: magnesium was given together with other treatments.
Sleep ME/CFS
Combination: CoQ10 / ubiquinol + Alpha-lipoic acid (ALA, R-ALA) + NAC (N-acetylcysteine) + L-carnitine + Magnesium + Vitamin C + Vitamin D and sun exposure + Vitamin E (tocopherol, tocotrienols) + Vitamin A (retinol) + Biotin + Thiamine / benfotiamine + Riboflavin (vitamin B2) + Niacinamide (nicotinamide) + Pantothenic acid (vitamin B5) + Vitamin B6 (pyridoxine, P5P) + Folate / folic acid supplements + Vitamin B1210 in the study
Mitochondrial modifying nutrients in treating chronic fatigue syndrome: A 16-week open-label pilot study (2017): ISI, better.
Shown, not counted: magnesium was given together with other treatments.
Quality of life ME/CFS
Combination: CoQ10 / ubiquinol + Alpha-lipoic acid (ALA, R-ALA) + NAC (N-acetylcysteine) + L-carnitine + Magnesium + Vitamin C + Vitamin D and sun exposure + Vitamin E (tocopherol, tocotrienols) + Vitamin A (retinol) + Biotin + Thiamine / benfotiamine + Riboflavin (vitamin B2) + Niacinamide (nicotinamide) + Pantothenic acid (vitamin B5) + Vitamin B6 (pyridoxine, P5P) + Folate / folic acid supplements + Vitamin B1210 in the study
Mitochondrial modifying nutrients in treating chronic fatigue syndrome: A 16-week open-label pilot study (2017): individual measures of the SF-12, no clear difference.
Shown, not counted: magnesium was given together with other treatments.
Autonomic symptoms Long COVID
Combination: Potassium + Magnesium144 with outcome data
Association between electrolyte supplementation and cardiac injury in long COVID-19. (2025): SDNN, better.
Shown, not counted: magnesium was given together with other treatments.
Quality of life Long COVID
Combination: Potassium + Magnesium144 with outcome data
Association between electrolyte supplementation and cardiac injury in long COVID-19. (2025): Minnesota questionnaire scores, better.
Shown, not counted: magnesium was given together with other treatments.
Side effects
Stopping because of side effects1 study
2 group A patients dropped out of the trial: a generalised rash, which might have been a side-effect of treatment, developed in 1 female patient
Red blood cell magnesium and chronic fatigue syndrome. (1991)
Doses studied
What researchers used, as the papers print it; not a recommendation.
- 1Start
200 to 400 mg at the start in most studies
- 2Top dose
Most often 64 mg (1 of 4 studies)
Doses across 4 studies
64 to 400 mg. One study of 60 people went up to 1300 mg.
Each study’s dose, as printed
- 64 mg, twice daily dosing Mitochondrial modifying nutrients in treating chronic fatigue syndrome: A 16-week open-label pilot study (2017)
- 200 mg, chewable tablets once a day for 90 days Role of nutrient supplements in children with post-COVID condition: a retrospective preliminary observation and narrative review. (2025)
- 1300 mg Combined oral supplementation with magnesium plus vitamin D alleviates mild to moderate depressive symptoms related to long-COVID: an open-label randomized, controlled clinical trial. (2024)
- 400mg/d, one capsule per day throughout the intervention period, preferably after lunch Can magnesium supplementation boost neuromuscular adaptations when combined with resistance training in Long COVID patients? (2025)
All papers
- Red blood cell magnesium and chronic fatigue syndrome.1991 · placebo trial · 38 randomised · 32 started
Summary
This randomised, double-blind, placebo-controlled trial asked whether intramuscular magnesium sulphate improves wellbeing in chronic fatigue syndrome (CFS). 38 patients were recruited from the Centre for the Study of Complementary Medicine and general practitioners in the Southampton area; 4 were excluded before randomisation, and 32 were randomised to magnesium sulphate 1 g in 2 ml every week for 6 weeks (15 patients) or placebo, 2 ml injectable water (17). Patients completed the Nottingham health profile before the first injection and a week after the last. Reductions in energy, pain, and emotional reactions scores were significantly greater in group A than in group B; the overall score was highly significantly improved for group A. 12 of 15 magnesium patients and 3 of 17 placebo patients said they benefited (difference 62%, 95% CI 35 to 90, p=0-0015). Before treatment, 11 group A patients scored the maximum 100 for energy; 7 scored the minimum 0 after treatment. Of 14 group B patients scoring 100 before treatment, 1 had a reduced score after treatment. Red cell magnesium was within the normal range in all group A patients after treatment and in only 1 group B patient. 2 group A patients dropped out; 1 had a generalised rash, which might have been a side-effect. The authors state the trial was small and follow-up only 6 weeks.
- Combined oral supplementation with magnesium plus vitamin D alleviates mild to moderate depressive symptoms related to long-COVID: an open-label randomized, controlled clinical trial.2024 · randomised trial · 60 randomised
Summary
This open-label randomized, controlled clinical trial enrolled 60 subjects with hypomagnesemia, vitamin D deficiency, and mild-to-moderate depression (MMD) related to long-COVID. Recruitment location was not reported. Participants were randomly allocated to an intervention group (n=30) receiving oral magnesium chloride 1300 mg plus vitamin D 4000 IU, or a control group (n=30) receiving oral vitamin D 4000 IU, for four months. The primary trial endpoint was improvement in depressive symptoms, defined as Beck Depression Inventory (BDI) <11. By comparing baseline with final measurements, the BDI score fell from 28.8±3.7 to 9.2±7.5 (p<0.01) in the intervention group and from 28.4±3.8 to 21.6±9.1 (p<0.05) in the control group. A total of 22 (73.2%) subjects in the intervention group and 10 (34.5%) in the control group reached a BDI <11, p=0.006. Mild adverse events that did not require withdrawal from intervention were documented in six (20.0%) and three (10%) individuals of the intervention and control group, respectively. The authors conclude that combined oral supplementation with magnesium plus vitamin D alleviates MMD related to long-COVID among patients with hypomagnesemia and vitamin D deficiency. The provided text did not state limitations.
- Use and Perceived Helpfulness of Different Intervention Strategies in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome and Depression.2026 · compared with another group · 819 in the study · 3,637 started
- Can magnesium supplementation boost neuromuscular adaptations when combined with resistance training in Long COVID patients?2025 · compared with another group · 8 in the study
Summary
Eight women with symptoms that could be associated with Long COVID for at least three months after the acute infection were allocated to a traditional resistance training protocol (TRAD, n=4) or the same resistance training plus magnesium dimalate (SUP, n=4) for six weeks. Training was performed two times a week, with 2 sets of 10 to 12 repetitions; the SUP group also took one capsule per day of 400mg magnesium dimalate. Outcomes measured before and after were DSQ-Covid symptom score, handgrip strength, biceps thickness, five times sit to stand test and timed up and go. The DSQ-Covid score was significantly reduced after the intervention only in the SUP group (1996.9 ± 425.2 AU vs 1309.4 ± 416.4 AU, p < .05), but there was no difference compared to RT without supplementation. A significant time effect was reported (F = 15.95, p = 0.01, partial eta2 = 0.76). Percent changes were 37.5% and 34.5% in TRAD and SUP. No statistical significance was observed within or between groups in muscle strength, thickness, and functional performance (p > .05). Handgrip changed +3.6% and +9.4%, 5TSTS -3.7% and -3.4%, TUG -9.4% only in TRAD, and biceps thickness +13.6% only in SUP. No participant had a session terminated early due to desaturation; no side effects of supplementation were reported; adherence was at least 80%.
- Improvement in Long COVID Brain Fog After Benfotiamine and Methylcobalamin Supplementation: Case Report Series and Review of the Literature2026 · case report · 3 in the study
Summary
This case series reports three people with Long COVID-related cognitive dysfunction (brain fog); one also had chronic fatigue syndrome/myalgic encephalomyelitis. All three self-administered an oral proprietary formulation of benfotiamine and methylcobalamin at differing doses: benfotiamine 150 mg, 300 mg, or 300 mg twice daily, with methylcobalamin 500 mcg, 1,000 mcg, or 12 mcg per day. There was no comparison group. Outcomes were patient-reported; no baseline thiamine or vitamin B12 biomarkers and no cognitive assessments were obtained before supplementation. Each patient described a noticeable benefit within a brief period ranging from several days to several weeks. In case 1, improvement in energy and mental clarity and resolution of brain fog were reported within three days. In case 2, improvements in mental clarity, executive function and confidence were reported within six weeks; after five weeks without the supplement, cognitive dysfunction recurred, and improved cognitive function returned within four to six weeks of resuming it. In case 3, brain fog and joint pain improved within 10 days, radicular pain resolved and dizziness improved by approximately 85% after 30 days. No serious adverse effects were reported by any patient; case 1 reported no adverse effects. The authors state the observations are hypothesis-generating and cannot establish causality.
- HERV Dysregulation in a Case of Myalgic Encephalomyelitis and Multiple Sclerosis Responsive to Rituximab.2025 · case report
Summary
This case report describes a single male patient in his 30s with a co-diagnosis of ME/CFS and MS, followed longitudinally. After a new MS relapse with radiological inflammation, he received rituximab at 1 g on days 1 and 15 of the first month, then nine monthly doses of 1 g adjusted by B-cell repopulation, a 9-month treatment regime. There was no comparison group; outcomes were before-versus-after observations in this patient. The report states a significant improvement in fatigue after the third dose, enabling increased mobility and participation in daily activities such as walking and dining out. On the Bell scale for severity assessment, the patient changed from a level of 10 to 20. After treatment he could leave the house 2–3 times a week and take gentle walks for an hour, and he reported a migraine once a month. The authors report he stayed in remission for at least 3 years after treatment. Harms of rituximab were not reported. The authors note limitations including sub-optimal frequency of MRI to monitor lesion progression and of HERV reassessment after rituximab, and the limited external validity of single study cases.
- Clinical characteristics of endocrine disturbances in post-COVID-19 condition, case report with review of literature2024 · case report · 5 in the study
Summary
This case report with review of literature reports on five patients with confirmed SARS-CoV-2 infection for over three months who were hospitalised in the Endocrinology Department of the Second Affiliated Hospital of Ningxia Medical University from June 12, 2023 to July 7, 2023 with post-COVID-19 condition (PCC). There was no comparison group. Treatments included ACTH injection, recombinant human GH injection, oral synthetic glucocorticoids (prednisone acetate or methylprednisolone), hydrocortisone, finerenone, and nirmatrelvir/ritonavir in one patient; duration and follow-up varied by patient, with follow-up at one week, one month, and three months. Dynamic endocrine testing included ITT, arginine stimulation test, rapid ACTH stimulation test, and supine–standing test; pituitary MRI and adrenal CT were performed in one patient. All five patients had hypothalamic syndrome with secondary adrenal insufficiency, growth hormone deficiency, and secondary hyperaldosteronism. The abstract states remarkable improvement was observed within one week for all patients; the Discussion states all patients showed remarkable improvement after just one to four weeks of multi-hormone combination therapy. One patient self-discontinued ACTH and rhGH one month later and reported regaining the ability to perform daily work. The authors write that the origin of these disturbances remains unclear and that discerning whether abnormalities in ACTH, cortisol, and GH secretion are attributable to hypothalamic damage is challenging in clinical practice.
- Oxygen-ozone therapy in meningoencephalitis and chronic fatigue syndrome. Treatment in the field of competitive sports: case report2019 · case report · 1 in the study
Summary
This was a case report of one patient, a 14-year-old boy who arrived in the Emergency Room of the authors' hospital for persistent hyperpyrexia, headache and prolonged emetic episodes and complaining of objective photophobia and dizziness. He was diagnosed with post-infectious chronic fatigue syndrome after meningoencephalitis. The patient was treated with oxygen-ozone therapy by rectal insufflation, 150 cc at a concentration of 35 mcg, at bi-weekly intervals for 4 weeks, continued weekly for a further 4 weeks, associated with Micetrin at double daily dosage for the first two weeks followed by single daily dosage for the entire treatment period. There was no comparison group. Outcomes concerned symptom remission and neurological examination. The report states complete remission of the symptoms of asthenic, neurological and clinical parameters, and complete remission of asthenic symptoms and regression of cephalic, vertiginous and myalgic symptoms. Two months after discharge, the Neurological Objective Examination was within normal limits with a slightly positive Romberg and some uncertainty in digital dexterity tests associated with nuanced bilateral tremor. Harms, worsening and withdrawals were not reported. The authors state no limitations.
- Chronic fatigue syndrome (CFS) associated with Staphylococcus spp. bacteremia, responsive to potassium arsenite 0.5% in a veterinary surgeon and his coworking wife, handling with CFS animal cases.2001 · case report · 2 in the study
Summary
This preliminary note reports two patients with chronic fatigue syndrome: a 38-year-old veterinary surgeon (the author) and his 32-year-old co-working wife, both meeting the CDC working case definition. They fell ill in September 1992 after handling CFS animal cases. The study had no comparison group. Both received potassium arsenite 0.5% (Fowler’s solution 1/2), 1 ml/12 h intramuscularly for 10 days (7.5 mg of As/day), from 10 to 20 February 1996; no other medicament was given contemporaneously. Outcomes included symptoms, Bell’s Questionnaire radial plot scores, blood smears, blood cultures, CK, LDH and CD4/CD8 ratio. Following treatment, both patients experienced complete remission; at the post-treatment control 1 month later, micrococci had disappeared from the blood. Patient #1’s Bell score was 138.5 before and 44 after treatment; patient #2’s was 141.5 before and 8 after (the discussion also prints 141.4). Patient #1 had decreased weakness and improved exercise tolerance in a few days, and muscular and joint pain ceased by day 10. Patient #2’s premenstrual symptoms disappeared by day 4, and weakness and joint pain had completely disappeared by day 10. Neither patient suffered relapses during the following 5 years (1996–2001). Side effects and withdrawals were not reported. The authors state that species identification could not be performed.
- [A case of chronic fatigue syndrome who showed a beneficial effect by intravenous administration of magnesium sulphate].1992 · case report · 1 in the study
Summary
The report describes one 29-year-old female with chronic fatigue syndrome, diagnosed using the working case definition proposed by Holmes et al., who was transferred to the authors' hospital in May 1991. The text says she had been treated for atopic dermatitis for 5 years. She had general malaise, low grade fever, lymph node swelling, headache, myalgias, muscle weakness, arthralgias and insomnia. Magnesium sulphate was given intravenously once a week for about 6-week's administration, with the aim of improving her condition, especially severe general malaise. There was no comparison group; the report describes a before-and-after course in this one patient. After about 6-week's administration of magnesium sulphate, she noticed reduced easy fatigability and an improvement in her impaired daily activities. Finally she was able to leave the hospital in January 1992. The abstract reports no side effects, no withdrawals and no worsening. No formal scale for easy fatigability or daily activities is reported, and no p-values or statistical comparisons are reported. The authors state no limitations in the abstract.
- Association between electrolyte supplementation and cardiac injury in long COVID-19.2025 · combination: given with other treatments · 144 with outcome data
Summary
This retrospective study at Guangdong Provincial People’s Hospital Zhuhai Hospital used data from patients with cardiac injury related to long COVID-19 admitted and managed between January 2021 and January 2023. The analysis included 144 patients: 72 received potassium and magnesium supplementation plus lifestyle advice, and 72 received lifestyle advice only. Data were collected at admission and 14 days later. Outcomes included heart rate variability parameters, the Minnesota Heart Failure Quality of Life questionnaire, numerical rating scale scores, and serum potassium and magnesium. At 14 days, the text reports higher potassium and magnesium levels in the supplementation group than in the control group. SDNN, rMSSD, and LF/HF were higher in the supplementation group, while HF and premature contraction were lower. Minnesota questionnaire scores and NRS scores were lower in the supplementation group. In the supplementation group, after 14 days compared with admission, SDNN was higher, premature contraction number was lower, and LF/HF was higher. The text reports comparable initial potassium and magnesium levels and no significant differences in initial Minnesota and NRS scores between groups. No patients with hyperkalemia or hypermagnesemia were observed; final hypokalemia was 0 (0.0) in the supplementation group and 7 (9.7) in the control group, and final hypomagnesemia was 0 (0.0) in both. Withdrawals with harms listed as the reason were not reported. The authors state limitations including a single-center retrospective observational design and variables limited to patient charts.
- Role of nutrient supplements in children with post-COVID condition: a retrospective preliminary observation and narrative review.2025 · combination: given with other treatments · 1,243 in the study · 1,171 with outcome data
Summary
This retrospective preliminary observation and narrative review asked whether nutrient supplements affected long COVID in children. It was a retrospective sub-analysis of a previously published prospective follow-up cohort at a Post-COVID clinic in a third-level hospital in Rome, Italy, from February 2020 to October 2022. During the study period 1243 patients were enrolled; 1171 were in the six-month follow-up table. Children with persistent, disabling symptoms at three months after infection received oral lactoferrin and/or a Multi-Element Product (MEP) as chewable tablets once a day for 90 days. Treatment groups were MEP plus lactoferrin (152 started), lactoferrin alone (18), and MEP alone (9). The outcome was persistence of long COVID at six months following initial infection. As reported, MEP alone (OR 5.7, 95% CI 3.8–8.5) and MEP plus lactoferrin (OR 5.06, 95% CI 3.3–7.6) were associated with a lower risk of long COVID at six months than lactoferrin alone (OR 7.6, 95% CI 5.1–11.4). For therapy started six months or longer after infection, no statistically significant associations were found with Long Covid resolution. Harms were not reported. The authors state the study was retrospective and had no control group, so causality and spontaneous improvement cannot be distinguished.
- Translating Results from The Womed Model of Benign Thyroid Disease to A Practical Approach to Treat Fatigue In COVID-19 Patients Based on Combined Supplementation with Magnesium, Selenium, and Coenzyme Q10: A Treatment Strategy against Fatigue2020 · combination: given with other treatments · 3 in the study
- Mitochondrial modifying nutrients in treating chronic fatigue syndrome: A 16-week open-label pilot study2017 · combination: given with other treatments · 10 in the study
Summary
This 16-week open-label pilot study examined a combination nutraceutical of mitochondrial agents in 10 patients with chronic fatigue syndrome recruited through clinicians and based at The Melbourne Clinic in Melbourne, Australia. Participants received twice-daily dosing of Co Q10, alpha lipoic acid, N-acetylcysteine, Acetyl L-carnitine, B vitamins and co-factors for 16 weeks, with no placebo comparison. Assessments occurred at baseline, W4, W8, W12 and W16 and included the Chalder Fatigue Scale (CFQ), MADRS, ISI, PGI, CGI-S, CGI-I, WSAS and SF-12. Mean total CFQ scores fell from 22.0 (6.07) at baseline to 12.6 (7.46) at Week 16 (F(4,29) = 6.31, p < 0.001); the baseline-to-Week 4 mean difference was 7.66 (p < 0.01). Nine of 11 CFQ items showed significant improvement, while memory (item 11) and problems starting things (item 4) did not. ISI (p = 0.017) and CGI-I (p = 0.014) improved; MADRS (p = 0.225), PGI (p = 0.33), CGI-S (p = 0.150), WSAS (p = 0.095) and SF-12 measures did not change significantly. Adverse events included headaches/migraines (n = 3), minor gastritis (n = 4), loss of appetite/feeling of fullness (n = 1), brief tachycardia (n = 1) and skin pigmentation on the forehead (n = 1); no serious adverse events were noted, and no participants withdrew due to adverse events. Two participants (20%) withdrew before termination, at week four and week twelve, due to work commitments.
- A multidimensional treatment plan for chronic fatigue syndrome1999 · combination: given with other treatments · 81 in the study · 64 with outcome data
Summary
This pilot study without a control group assessed a cumulative multidimensional treatment plan in 81 patients with chronic fatigue syndrome fulfilling Oxford criteria, referred to the Glasgow Homoeopathic Hospital. Treatment was added monthly over 6 months: a wheat-free diet with nutritional supplements, then homoeopathic treatment of allergies, then homoeopathic constitutional remedies, then psychotherapeutic techniques for self-image and inner resources. Outcomes were clinical evaluation and six questionnaires. Sixty-four patients completed the study. Of these, 45 (70%) reported clinical improvement with a positive effect on daily living; the same patients reported improvement in the six questionnaire scores, apart from 4 patients who did not improve their scores in two tests. No patient deteriorated. Mean monthly questionnaire scores declined steadily over the first four months and then steadied; scores after 4 months were significantly lower than on entry for the group as a whole and for the allergic, non-allergic and female subgroups, but not for the men. More women improved than men (38/51 versus 7/13), a difference reported as not quite significant. Patients with and without allergies were reported to improve to the same extent. Seventeen patients dropped out: 2 could not organize the wheat-free diet, 1 was a baker, 2 withdrew on religious grounds related to the ego-strengthening exercises, 4 improved but did not complete, and the reasons for the remaining 8 were not ascertained. The authors call for a randomized controlled trial.
- Clinical effectiveness of rehabilitation in ambulatory care for patients with persisting symptoms after COVID-19: a systematic review.2023 · systematic review
Summary
This systematic review asked whether rehabilitation treatments applicable in ambulatory care help adults with persisting symptoms after COVID-19. Searches on 9 May 2022 identified 45,479 records, and 38 studies comprising 2,790 participants were included. Interventions included physical training, breathing exercises, nutritional supplements, olfactory training, multidisciplinary treatment, and other treatments such as hyperbaric oxygen therapy; treatment duration was not reported. Comparisons varied, including low- versus high-intensity training in 76 men and advanced versus classical olfactory training in 80 patients. Outcomes included fatigue, dyspnoea, pain, physical capacity, pulmonary function, sensory function, quality of life, return to activities, functional capacity, and adverse events. Physical training and breathing exercises may reduce fatigue, dyspnoea, and chest pain and may improve physical capacity and quality of life, with very weak evidence; improvement was not demonstrated for muscle pain or return to work. Low-intensity training increased handgrip strength and quality of life compared with high-intensity training. Advanced olfactory training was not superior to classical training. Hyperbaric oxygen therapy can have beneficial effects on fatigue in one cohort of 10 patients. Side effects with olfactory training occurred in 18 out of 80 participants. Reported adverse events included hospitalisations, dizziness, symptom exacerbation such as fatigue, headache in one participant, and post-exertional malaise after exercise.
- Role of dietary modification in alleviating chronic fatigue syndrome symptoms: a systematic review.2017 · systematic review
Summary
This systematic review asked whether dietary modification alleviates chronic fatigue syndrome (CFS) or myalgic encephalomyelitis (ME) symptoms. It searched Scopus, CINAHL Plus, Web of Science and PsycINFO from 1994 to 2014 in May 2014, with an update from June 2014 to August 2016, and included 22 studies across animal and human designs. Treatments included D-ribose, probiotic, oral vitamin D3, vitamin and mineral supplements, polynutrient supplementation, magnesium, calcium, ginseng, EFA supplements, glutamine, a low-sugar low-yeast diet, and polyphenols (AMF, EGCG, naringin). D-ribose showed significant improvement in energy levels in compliant analysis (p<0.0001, 95%CI 1.1–2.2), and 65.7% reported improved overall subjective feelings. Probiotic: six of 15 reported subjective improvement and neurocognitive measures improved (p=0.04), but no significant overall change. Vitamin D3 showed no statistically significant improvement in fatigue or inflammatory/oxidative markers. One vitamin/mineral supplement showed improvements in fatigue (p=0.0009) and some quality-of-life measures; another found no significant relationship. Polynutrient supplementation found no significant results. Magnesium improved fatigue at six months (p=0.002) but not at two years; calcium improved fatigue (p=0.01) based on five participants; ginseng was most helpful in 56%. An EFA case study dropped depression scores from 27 to 3 at 16 weeks; an EFA versus sunflower-oil placebo trial found no significant difference. Glutamine showed no significant symptom change; placebo showed decreases in emotionality and sleep problems (p=0.02). The low-sugar low-yeast diet showed no significant difference. Animal polyphenol studies reported significant improvements (p<0.05). The review did not report side effects or withdrawals.
- Chronic fatigue syndrome.2011 · systematic review
Summary
This systematic review asked what the effects of treatments for chronic fatigue syndrome are. The authors searched Medline, Embase, The Cochrane Library and other databases up to March 2010, included 46 systematic reviews, RCTs or observational studies, and rated the quality of the evidence with GRADE. They list the treatments covered: antidepressants, cognitive behavioural therapy, corticosteroids, dietary supplements, evening primrose oil, galantamine, graded exercise therapy, homeopathy, immunotherapy, intramuscular magnesium, oral nicotinamide adenine dinucleotide and prolonged rest. The abstract gives no finding for any of them and names no included study, so no results are listed here.
- Complementary and alternative medicine for patients with chronic fatigue syndrome: a systematic review.2011 · systematic review
Summary
This systematic review examined randomised controlled trials of complementary and alternative medicine (CAM) for patients with chronic fatigue syndrome (CFS), also termed myalgic encephalomyelitis (ME). The search was up to 13th August 2011. A total of 26 RCTs, which included 3,273 participants, met the inclusion criteria. The CAM therapies included mind-body medicine, distant healing, massage, tuina and tai chi, homeopathy, ginseng, and dietary supplementation. The review reports that studies of qigong, massage and tuina demonstrated positive effects, whereas distant healing failed to show a significant effect on mental or physical components of quality of life. Compared with placebo, homeopathy had insufficient evidence of symptom improvement in CFS. Most supplements failed to show beneficial effects for CFS, with the exception of NADH and magnesium. Five of the 26 included studies reported no adverse events or a slight occurrence of them, and the other included studies lacked descriptions regarding adverse events; no severe adverse effects of CAM were noted. The authors state that firm conclusions are difficult with the limited number of RCTs for each therapy, small sample sizes and high risk of bias.
- Alternative medical interventions used in the treatment and management of myalgic encephalomyelitis/chronic fatigue syndrome and fibromyalgia.2010 · systematic review
Summary
The review included 70 controlled clinical trials of alternative and complementary treatments and nonpharmacological supplements for ME/CFS and fibromyalgia; searches ran up to April 2007. It did not have its own treatment arm or comparison group; it summarized trials with control or comparison conditions. The review did not report one treatment dose or duration. Outcomes in included trials covered laboratory tests, physical functioning, psychologic functioning, and quality of life. The review reports that some trials showed at least one positive effect and some showed null or ambiguous results; it states that no firm conclusions can be made. Only three studies (4%) reported adverse side-effects such as bruising and rashes. For acupuncture, three RCTs reported dropout rates of around 15%–35% in all intervention groups. The authors state publication bias: beneficial effects tend to be published while negative results may remain unpublished. They also state the methodological quality of reporting was generally poor and that no definite CAM treatment recommendations can be made for ME/CFS or FM.
- Interventions for the treatment, management and rehabilitation of patients with chronic fatigue syndrome/myalgic encephalomyelitis: an updated systematic review.2006 · systematic review
Summary
This updated systematic review asked whether any intervention is effective for treatment, management or rehabilitation of adults and children with CFS/ME. The authors searched eleven electronic databases and included 70 studies, of which 59 were RCTs; comparisons were between treatment and control groups. Interventions included CBT, GET, rehabilitation, immunological and pharmacological treatments, supplements and complementary therapies. Outcomes covered physical, psychological, laboratory/physiological and quality-of-life measures. CBT and GET appeared to reduce symptoms and improve function based on RCTs. In a CBT trial (n=69), physical functioning, fatigue and symptoms favoured CBT (P<0.003) and school attendance favoured treatment (P=0.04). Another CBT trial (n=65) found no significant difference for fatigue, anxiety and depression, or disability. In GET trials, CGI and fatigue favoured treatment (n=49; P<0.03), and fatigue and depression/anxiety were significantly better (n=61; P=0.027). One GET trial reported withdrawal of one patient in each group because of worsening symptoms; eleven patients withdrew because of adverse events in a GET with or without fluoxetine trial. Galantamine (n=434) showed no significant differences; 130 patients withdrew, 389 reported adverse events and 88 withdrew. Acetyl-L-carnitine and propionyl-L-carnitine (n=90) improved general fatigue in PLC (P=0.004) and combined group (P<0.001), and mental fatigue in ALC group (P=0.015); 8 patients withdrew due to side effects. Staphylococcus toxoid (n=98) had 13 treatment-group and 7 placebo-group patients with side effects. Hydrocortisone/fludrocortisone (n=80) found no significant differences.
- Interventions for the treatment and management of chronic fatigue syndrome: a systematic review.2001 · systematic review
Summary
This systematic review asked whether interventions for chronic fatigue syndrome (CFS) work. Nineteen specialist databases were searched, and 44 trials met inclusion criteria: 36 randomized controlled trials and 8 controlled trials. Treatments were grouped by type and compared with control conditions. Outcomes were classified as positive, negative, or no effect. Three randomized controlled trials of GET all showed an overall beneficial effect compared with control groups. Three of four randomized controlled trials of CBT found a positive overall effect; one controlled trial did not find overall beneficial effects. One randomized controlled trial found no effect of fluoxetine either alone or with GET. Hydrocortisone showed an overall beneficial effect in one randomized controlled trial and some beneficial effects in another. For immunoglobulin, two randomized controlled trials showed an overall beneficial effect, two showed some positive effects, and the largest reported no effect. Acyclovir showed a negative effect for one outcome. Randomized controlled trials of fludrocortisone, antidepressants, moclobemide, sulbutiamine, growth hormone and galanthamine hydrobromide found no effects. Oral NADH showed an overall beneficial effect in one randomized controlled trial. Harms included withdrawals from immunoglobulin therapy (2 due to severe constitutional symptoms, 1 due to a skin eruption, 1 due to mild but transient liver failure, 1 due to phlebitis, and 2 whose adverse effects were not reported), 3 withdrawals from acyclovir due to reversible renal failure, and 2 participants leaving the magnesium group after a generalized rash. CBT trials had a dropout rate of 19% (114/589), GET trials 18% (68/370), and pharmacological trials 11% (99/869).
- Impact of nutrition on long COVID.2026 · review
Summary
This narrative review examined nutritional and exercise interventions for long COVID; it did not report its own cohort. It describes a single-site RCT with n = 151 participants; n = 98 received VitK2/D3 and n = 53 received standard of care, and participants who received Vit K2/D3 showed a 7.1% reduction in long COVID symptoms compared to control group. A randomized, double-blind, placebo-controlled trial with n = 80 patients (n = 40 post COVID patients; n = 40 placebo) gave 60 000 IU of Vitamin D weekly for 8 weeks; the vitamin D group showed significant improvements in CFQ, DASS-anxiety and ACE, but no significant changes were found PQSI, DASS depression, TMT, IL-6 or CRP levels; Table 2 entry 11 reported this vitamin D supplementation with very low side effects. A multicentre trial with n = 144 patients (n = 71 vitamin D3 group; n = 71 placebo group) gave a single oral dose of 200 000 IU Vitamin D3 and found no significant differences between Vit D3 and placebo group for listed symptoms and quality of life upto 1 year of follow up. Probiotic mixture VSL#3® reduced fatigue and significantly improved physical functioning and gasterointestinal symptoms. Stopping or worsening was not reported. The review states limitations in trial design.
- A Comprehensive Scoping Review on Diet and Nutrition in Relation to Long COVID-19 Symptoms and Recovery.2025 · review
Summary
This scoping review synthesized 50 studies (27 intervention and 23 observational) in adults with long COVID-19, identified through database and manual searches. The review itself had no comparison group and no meta-analysis. Included studies examined vitamin D, multinutrient/nutraceutical formulations, amino acids and metabolic support, creatine, oxaloacetate, nitric-oxide boosters, gut microbiota-targeted therapies, and diet/lifestyle programs; comparisons included placebo, controls, or another formulation. Examples reported: in 80 people with post-COVID-19 syndrome, weekly vitamin D improved fatigue (p = 0.024), anxiety (p = 0.011), and cognitive function (p = 0.012), with no effects on depression, sleep quality, or inflammatory markers. A single 200,000 IU vitamin D3 dose in 144 hospitalized patients showed no benefit on persistent symptoms or quality of life. Magnesium plus vitamin D improved depression (73.2% vs 34.5% remission, p = 0.006). PIRV-F20 in 44 long COVID-19 patients improved six-minute walking distance (+40 m vs +10 m, p = 0.02) but not strength or symptoms. Noni in 188 post-COVID-19 patients reduced fatigue (61.5% vs 24.3%), cognitive symptoms (59.4% vs 21.6%), and joint pain (66.2% vs 33.8%). SIM01 in 463 individuals alleviated core symptoms (all p < 0.01). Beetroot juice in 31 patients showed no significant between-group differences. Side effects and withdrawals were not reported in the recorded data. The authors state no formal quality appraisal was performed and causal inferences cannot be made.
- Management of chronic fatigue syndrome/myalgic encephalomyelitis in a pediatric population: A scoping review.2020 · review
Summary
This scoping review examined peer-reviewed research on managing chronic fatigue syndrome/myalgic encephalomyelitis (CFS/ME) in a pediatric population aged under 18 years. The authors searched electronic databases and included 29 peer-reviewed research articles; no new participants were enrolled. The review grouped findings under nutrition/dietary components, exercise therapy, psychosocial factors, and multifaceted treatment. Included studies evaluated CBT with biofeedback, the Lightning Process plus standard medical care, aerobic graded exercise versus progressive resistance training, graded activity/exercise with family sessions, dietary changes, pacing versus STAIRway to Health, and other programs. Outcomes included fatigue severity, school attendance, physical function, anxiety and depression, quality of life, and global health. The review reports that included studies found lower fatigue severity and higher school attendance with CBT plus biofeedback, improvement with Lightning Process plus standard medical care, and no significant difference between aerobic graded exercise and progressive resistance training for physical capacity and QOL, while fatigue and depressive symptoms improved only in the aerobic group. No harms, side effects, worsening or withdrawals were reported in the recorded data. The authors state a lack of research in younger children and insufficient evidence for dietary modifications or supplements in prepubescent children.
- Treatment and management of chronic fatigue syndrome/myalgic encephalomyelitis: all roads lead to Rome.2017 · review
Summary
This comprehensive review examines benefits and harms of treatments for CFS/ME and makes recommendations. It reports no single enrolled or analysed total. Among the included studies, a phase II rintatolimod trial had 92 patients and a phase III trial had 234 patients; a rituximab RCT had 30 patients, with sustained overall improvement in 67% of CFS/ME patients versus 13% of controls. The PACE trial had 640 patients; a recovery paper reported 22% recovered in the CBT and GET groups, compared with 8% in the APT group and 7% in the SMC-only group. A survey of 828 Norwegian CFS subjects reported pacing useful in 96%, and 79% of patients with experience of graded training considered it worsened their health. CoQ10 plus NADH was studied in 80 patients, with maximum heart rate p=0.022. The review also describes harms: three patients administered acyclovir withdrew due to reversible renal failure, and two out of 13 participants developed neutropenia. The authors state no firm conclusions can be drawn because the few RCTs were small-scale, with a high risk of bias, and used different case definitions; nutritional studies were very limited, mostly small and without long-term follow-up.
- Treating chronic fatigue syndrome - a study into the scientific evidence for pharmacological treatments.2011 · review
Summary
The paper reports a questionnaire survey of 94 CFS patients from Queensland and New South Wales, recruited through support groups and newspaper and email advertisements, plus a search for randomised controlled trials. Patients filled out a questionnaire on current medicines and supplements; no treatment was given by the authors, and the survey had no comparison group. The 94 patients used 474 different medicines and supplements. Commonly used were antidepressants (41%), sedatives (27%), B vitamins (47%), magnesium (24%) and co-enzyme Q10 (7%). The search identified 20 RCTs. Findings included no difference for fluoxetine on fatigue or SF-36, no difference between treatment and placebo on individual questionnaires, and no effect for several agents including phenelzine, moclobemide, valaciclovir, terfenadine, melatonin, ginseng, bovine liver extract and a polynutrient supplement. One hydrocortisone trial reported 87% rated themselves improved versus 17% on placebo (p<0.001); another reported 53% vs. 29% (p=0.04) improvement in wellness score. Harm notes included diarrhoea with high-dose oral magnesium, long-term adrenal gland suppression with adrenal hormones, addiction and loss of effectiveness with benzodiazepines and opiates, and hormonal/lipid changes with DHEA. No worsening or stopping was reported. The authors state limitations.
- Chronic fatigue syndrome: is there a role for non-antidepressant pharmacotherapy?2010 · review
Summary
This review examined pharmacotherapy for chronic fatigue syndrome (CFS), also called myalgic encephalomyelitis (ME), focusing on non-antidepressant controlled drug trials published between 1988 and August 2009. It did not report one overall number of enrolled patients. In the methylphenidate trial (60 CFS patients), clinically significant improvement on the Checklist of Individual Strength concentration subscale occurred in 13 patients taking methylphenidate (22%) versus three taking placebo (5%; p = 0.01); the number needed to treat was 6 [95% CI: 4.6 to 8.6]. A clinically significant fatigue response occurred in 10 patients (17%) with methylphenidate versus no patients with placebo; the number needed to treat was 6 (95% CI: 3.8 to 14.4). No effect was observed on bodily pain, mental health, depression and anxiety, and no severe side effects were reported. Other reviewed trials reported no significant effect for aciclovir, no beneficial effects for ganciclovir, no differences versus placebo for oral terfenadine (n = 30), and no effect for immunoglobulin in a large RCT (n = 99). In a doxycycline RCT (n = 491), there were no statistically significant differences versus placebo; the doxycycline group had a higher incidence of nausea and photosensitivity. Two participants in a magnesium RCT (n = 34) dropped out, one because of generalized rash.
- Use of exercise for treatment of chronic fatigue syndrome.1996 · review
Summary
This review summarises chronic fatigue syndrome (CFS) and the effects of exercise; it reports no new trial and gives no setting or total number of patients enrolled. It describes cited studies in CFS and fibromyalgia. In fibromyalgia, Goldman had previously inactive patients perform structured activity and reported that approximately 80% showed clinical improvements; McCain et al. had patients undergo aerobic exercise and reported that 50% showed clinical improvement and improved fitness measured by heart rate during submaximal exercise. In CFS, Behan et al. reported symptom improvement in 85% of the fish oil group compared with 17% for placebo after 3 months (63 study participants in total). Cox et al. reported similar success rates in 32 CFS patients after intramuscular magnesium sulfate injections. In one study, aciclovir or placebo was given to 27 CFS patients, with no correlation between treatment, symptoms or immunological profile. Prospective double-blind studies of intravenous immunoglobulin generally found no improvement above traditional treatments. One study reported CFS patients in support groups clearly do worse over the long term. Harms noted include that CFS patients are often unusually sensitive to adverse drug effects; excessive exercise may exacerbate CFS symptoms; relapses after exercise are reported, starting 6 to 48 hours after exercise and lasting 2 days to 2 weeks; in a preliminary study, only 1 of 16 patients had a significant relapse after a maximal treadmill exercise test.
- Treatment of the chronic fatigue syndrome. A review and practical guide.1993 · review
Summary
This review examined treatment of chronic fatigue syndrome (CFS); no review-level enrollment or follow-up numbers are reported. It summarized pharmacological and nonpharmacological therapies, including antidepressants, antivirals, immune modifiers, vitamins and minerals, essential fatty acids, CBT and psychotherapy, and benzodiazepines. Among cited trials, Straus et al. 1988a randomized 27 patients to aciclovir or placebo; 11 in the aciclovir group and 10 in the placebo group reported improvement. DuBois 1986 reported 53 vs 32% improvement with intramuscular gammaglobulin in 19 patients. Lloyd et al. 1990b reported 43% vs 12% improvement with intravenous immunoglobulin, while Peterson et al. 1990 found no objective advantage. Cox et al. 1991 reported 80% vs 18% improvement with magnesium sulphate in 32 patients. Behan et al. 1990 reported 85% vs 17% physician-rated improvement and 84% vs 22% self-rated feeling better with Efamol Marine in 70 patients; McBride & McCluskey 1991 reported an unpublished 6-month trial in 98 patients that found no difference. Butler et al. 1991, an uncontrolled pilot in 50 patients, reported improvement in 70% starting and disability improvement in 60% completing; Lloyd et al. 1993 did not find CBT beneficial in a double-blind trial of 90 patients. Harms included considerable adverse effects with aciclovir; serious and life-threatening side effects with mismatched double-stranded RNA (hepatic toxicity, arrhythmias, severe abdominal pain); exacerbation of myalgias, arthralgias and palpitations with interferon-a; and worsening symptoms in 10 patients given prednisolone with or without azathioprine. The authors state no established recommendations, with antidepressants most promising but lacking randomised, double-blind, placebo-controlled studies.